Irvine, CA, September 26, 2019 – Yesterday, an article, “CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies”, has been published at Science Translational Medicine.
To find the article on the web: https://stm.sciencemag.org/content/11/511/eaaw9414
About PeproMene Bio
PeproMene Bio, Inc. is a virtual, privately funded biotech company located Irvine, CA. We are developing novel immune-oncology therapies such as BAFF-R CAR-T therapy based on the novel antibodies. The BAFF-R CAR-T therapy program which was discovered and developed from Dr. Larry Kwak’s lab at MD Anderson and City of Hope was successfully licensed in from City of Hope, Duarte CA, in April 2017. Currently the further development is ongoing at City of Hope for its IND enabling study. We will continue to license-in and explore more of novel immuno-oncology programs via our network. For more information about the Company, please visit www.pepromenebio.com.
Contact
Steve Lee: 714-599-8077, steve@pepromenebio.com
